Roth Capital Downgrades Seelos Therapeutics (SEEL) to Neutral, Following Clinical Business Update

May 17, 2021 1:44 PM EDT
Get Alerts SEEL Hot Sheet
Price: $2.08 -5.45%

Rating Summary:
    6 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 13 | New: 29
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Roth Capital analyst Jonathan Aschoff downgraded Seelos Therapeutics (NASDAQ: SEEL) from Buy to Neutral with a price target of $4.00 (from $12.00).

For an analyst ratings summary and ratings history on Seelos Therapeutics click here. For more ratings news on Seelos Therapeutics click here.

Shares of Seelos Therapeutics closed at $5.19 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Roth Capital